DiosCURE Therapeutics SE

DiosCURE is advancing next-generation best-in-class immunotherapeutics to prevent and treat SARS-CoV-2 in order to combat the ongoing coronavirus pandemic. Due to their small size, our drug candidates can attach to unique surface structures of the SARS-CoV-2 spike protein.

This passive immunization approach will block the virus’ penetration into target cells which inhibits viral spreading and thereby allows the prevention and treatment of SARS-CoV-2 infections.

We build on a strong scientific foundation of a collaborative effort by the Institute of Innate Immunity of the University Hospital Bonn, The Scripps Research Institute San Diego and the Karolinska Institutet Stockholm. The discovery of our lead candidates was published in the journal Science.